MedTrace Logo

A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD

NCT01959022 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-10-20

No results posted yet for this study

Summary

This study will assess the effects of the medication doxazosin on sleep in men and women with PTSD. Sleep will be measured objectively at home using a portable sleep recorder and wrist actigraphy.

Conditions

  • Stress Disorders, Post-Traumatic

Interventions

DRUG

Doxazosin XL

Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Northern California Institute of Research and Education

    collaborator OTHER

  • San Francisco Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Anne Richards, MD, MPH · San Francisco Veterans Affairs Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959022 on ClinicalTrials.gov